Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face

Background. For large basal cell carcinomas (BCCs) of the head and neck, definitive surgery often requires extensive resection and reconstruction that may result in prolonged recovery and limited cosmesis. Vismodegib, a small-molecule inhibitor of the hedgehog pathway, is approved for advanced and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Block, Alec M., Alite, Fiori, Diaz, Aidnag Z., Borrowdale, Richard W., Clark, Joseph I., Choi, Mehee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609426/
https://www.ncbi.nlm.nih.gov/pubmed/26504605
http://dx.doi.org/10.1155/2015/827608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609426/
https://www.ncbi.nlm.nih.gov/pubmed/26504605
http://dx.doi.org/10.1155/2015/827608

Ejemplares similares